Printer Friendly

Just Published: "Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015".

[USPRwire, Thu Feb 04 2016] Global Markets Direct's, 'Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015', provides an overview of the Burkholderia pseudomallei Infections (Melioidosis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and special features on late-stage and discontinued projects.

Full Report Details at


Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

* The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)

* The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

* The report reviews key players involved in the therapeutics development for Burkholderia pseudomallei Infections (Melioidosis) and enlists all their major and minor projects

* The report summarizes all the dormant and discontinued pipeline projects

* A review of the Burkholderia pseudomallei Infections (Melioidosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Copyright [c] 2016 USPRwire Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Date:Feb 4, 2016
Previous Article:Human Insulin Market - Forecasts to 2020: New research report available at Fast Market Research.
Next Article:Just Published: "China Sleep Apnea Diagnostic Systems Market Outlook to 2021".

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters